Samjin to file patent of new therapeutic compound for C hepatitis.

Published: 2006-02-20 06:58:00

Updated: 2006-02-20 06:58:00

Samjin has filed the patent registration to the Patent Office for a new pyrimidinedione derivative developed by Central Research Institute as an anti-viral agent, having an anti-viral activity against C hepatitis virus, which may lead to the possible prevention and treatment of C hepatitis by sup...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK